More IDO Issues: NewLink Drops Pancreatic Cancer Indication For Indoximod
Executive Summary
NewLink has scrapped plans to explore its IDO inhibitor in pancreatic cancer – more bad news for a drug class that has suffered several setbacks recently.
You may also be interested in...
iTeos Says Adios To IDO And Eyes US IPO
An oversubscribed financing round led by new US investor MPM Capital has brought in $75m for the Belgian company. Much of it will be used to advance its potential best-in-class adenosine A2A receptor now that its IDO1 drug has been shelved.
NewLink CEO Reflects On Golden Age And Rapid Fall Of IDO
There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.
A Wake For IDO: Bristol Ends Registrational Trials Of High-Priced Flexus Drug
Following termination of pivotal trials in three tumor types testing its in-house IDO inhibitor BMS-986205, Bristol says it is "working quickly" to assess the development of Opdivo with Incyte's epacadostat.